<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Atrial fibrillation: Catheter ablation</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Atrial fibrillation: Catheter ablation</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Atrial fibrillation: Catheter ablation</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Rod Passman, MD, MSCE</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Bradley P Knight, MD, FACC</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">N A Mark Estes, III, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Susan B Yeon, MD, JD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 24, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>The three principal goals of therapy in patients with atrial fibrillation (AF) are the alleviation of symptoms, the prevention of tachycardia-mediated cardiomyopathy, and the reduction in the risk of stroke. The first two goals can be achieved with either a rate or rhythm control strategy (see  <a class="medical medical_review" href="/d/html/1045.html" rel="external">"Management of atrial fibrillation: Rhythm control versus rate control"</a>). For patients in whom a rhythm control strategy is chosen, catheter ablation (CA) and antiarrhythmic drug therapy are the two principle therapeutic strategies to reduce the frequency or eliminate episodes of AF. (See  <a class="medical medical_review" href="/d/html/93920.html" rel="external">"Maintenance of sinus rhythm in atrial fibrillation: Catheter ablation versus antiarrhythmic drug therapy"</a>.)</p><p>This topic will discuss the use of CA in patients with AF and provide the clinician with much of the information needed to discuss the procedure with the patient. The discussion of surgery to prevent recurrent AF is found elsewhere. (See  <a class="medical medical_review" href="/d/html/1046.html" rel="external">"Atrial fibrillation: Surgical ablation"</a>.)</p><p>Stroke prevention is usually achieved with anticoagulation. This topic is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/1031.html" rel="external">"Atrial fibrillation in adults: Use of oral anticoagulants"</a>.)</p><p class="headingAnchor" id="H4175884865"><span class="h1">WHAT TO TELL YOUR PATIENT</span><span class="headingEndMark"> — </span>When discussing CA to reduce symptoms in an AF patient, the following information should be provided:</p><p class="bulletIndent1"><span class="glyph">●</span>CA is a reasonable treatment option for AF patients when medications are unable to adequately control symptoms, are not tolerated, or not preferred.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>All patients who undergo CA must take oral anticoagulation for at least two to three months after the procedure. Anticoagulation should be continued long term in many patients with risk factors for stroke even if AF is not clinically present after the ablation. This is because patients may continue to have some AF episodes that may be asymptomatic; in addition, the reduction in AF burden seen post-ablation has not yet been shown to reduce stroke risk. It is a common misconception that patients who undergo successful ablation can stop oral anticoagulation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>About 70 to 75 percent of patients are symptom free at one year [<a href="#rid1">1</a>]. A lower percentage is likely for persistent AF (about 60 percent).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>About 50 percent of patients have detectable AF at one year (this includes symptomatic and asymptomatic patients) [<a href="#rid2">2,3</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The success rate for ablation in patients with long-standing persistent AF (over one year) is poor.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The risk of a major complication is about 4 percent, with vascular access complications being the most common. Other important, less common complications include stroke, cardiac perforation, or damage that includes injury to the pulmonary veins, esophagus, or phrenic nerve.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The risk of dying within 30 days after an AF ablation procedure is about 1 in 1000 patients.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The risk of a major complication is significantly higher at low-volume ablation centers. [<a href="#rid4">4</a>].</p><p></p><p class="headingAnchor" id="H61687779"><span class="h1">TECHNICAL CONSIDERATIONS</span><span class="headingEndMark"> — </span>Technical considerations for CA are presented separately. (See  <a class="medical medical_review" href="/d/html/95704.html" rel="external">"Catheter ablation for the treatment of atrial fibrillation: Technical considerations for non-electrophysiologists", section on 'Ablation techniques and targets'</a>.)</p><p class="headingAnchor" id="H1057443940"><span class="h1">COMPARISON WITH ANTIARRHYTHMIC THERAPY</span><span class="headingEndMark"> — </span>For patients with <strong>symptomatic paroxysmal</strong> AF, either a trial of an antiarrhythmic drug or CA is a reasonable first-line approach. We are more inclined to perform CA in patients for whom the odds of success are high and if they prefer to avoid the use of long-term antiarrhythmic drug therapy. Studies comparing these strategies are discussed separately. (See  <a class="medical medical_review" href="/d/html/93920.html" rel="external">"Maintenance of sinus rhythm in atrial fibrillation: Catheter ablation versus antiarrhythmic drug therapy", section on 'Patients without prior antiarrhythmic drug treatment'</a>.)</p><p class="headingAnchor" id="H20"><span class="h1">EFFICACY</span><span class="headingEndMark"> — </span>CA leads to significant symptom improvement in most patients. Over 70 to 75 percent are symptom free at one year. Some symptoms may be due to atrial or ventricular premature complexes rather than AF.</p><p>The absence of symptomatic AF recurrence is the primary efficacy outcome in most studies. However, with continuous invasive monitoring, approximately 50 percent of patients have had one or more documented episodes lasting 30 seconds or longer at one year. This becomes part of the rationale to continue long-term oral anticoagulation in many patients. (See  <a class="medical medical_review" href="/d/html/94502.html" rel="external">"Catheter ablation to prevent recurrent atrial fibrillation: Anticoagulation", section on 'Our approach to anticoagulation'</a>.)</p><p class="headingAnchor" id="H3788448901"><span class="h2">How is recurrence defined and measured?</span><span class="headingEndMark"> — </span>Recurrence of AF after CA is categorized as early or late. Each have distinct mechanisms and management implications [<a href="#rid5">5</a>]. From a clinical perspective, recurrences after the initial two-to-three-month post-ablation healing phase are more clinically relevant.</p><p>Early recurrences of AF are defined as those that occur within the first two to three months after CA. This period is often referred to as the "blanking period," and recurrences during this time are not included in studies examining the long-term success of AF ablation. Early recurrences occur as often as 40 percent of the time with radiofrequency ablation (RFA) [<a href="#rid6">6</a>] and about 17 percent of the time for those treated with cryoballoon [<a href="#rid7">7</a>]. It is postulated to be related to several potential mechanisms including sterile pericarditis, recovered pulmonary vein (PV) conduction, or proarrhythmic effects of the ablation procedure [<a href="#rid8">8</a>]. Some studies suggest that early recurrence appears to be a predictor of late recurrence, especially when the episodes occur late in the blanking period. However, most clinicians will treat early recurrences with antiarrhythmic drug therapy before consideration of repeat ablation in these patients. Episodes of AF occurring after three months are considered to be recurrent AF and are referred to as "late recurrent AF." The possible mechanisms for late recurrent AF following CA are discussed separately. (See  <a class="medical medical_review" href="/d/html/16402.html" rel="external">"Mechanisms of atrial fibrillation", section on 'Specific clinical situations'</a>.)</p><p>The frequency of late recurrent AF varies significantly across studies in part due to factors such as the method and intensity of surveillance, whether other atrial arrhythmias such as atrial flutter are counted, whether patients remained on antiarrhythmic drug therapy, and patient characteristics (eg, paroxysmal or persistent AF). In some studies, success has been defined as the absence of recurrent AF or other atrial arrhythmias with or without antiarrhythmic drug therapy; a more rigorous definition requires the absence of AF &gt;30 seconds in patients not taking antiarrhythmic drugs.</p><p>The following studies illustrate the rates of late recurrence [<a href="#rid9">9</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>The DISCERN AF study evaluated episodes of symptomatic and asymptomatic AF (as well as atrial flutter and atrial tachycardia) before and after the procedure in 50 patients (80 percent with paroxysmal AF), using an implantable cardiac monitor capable of recording all AF episodes [<a href="#rid10">10</a>]. The total atrial arrhythmia burden was significantly reduced by 86 percent from a mean of two hours per day per patient before to 0.3 hours per day after. The ratio of asymptomatic to symptomatic episodes increased significantly after ablation from 1.1 to 3.7. After 18 months and a mean of 1.4 ablations, 58 percent of patients were symptom free.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A 2023 meta-analysis of 73 studies (67,159 patients) with outcomes at &gt;5 years found that the freedom from atrial arrhythmia was around 51 percent [<a href="#rid11">11</a>]. With multiple procedures, the success rate was nearly 70 percent. Results were better for those with paroxysmal compared with persistent AF but comparable between radiofrequency and cryoballoon ablation. Limitations of the analysis include the possibility of publication bias, significant heterogeneity among individual publications, and disparities in postablation AF surveillance.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In the MANTRA and RAAFT-2 randomized trials, which allowed for antiarrhythmic drug use after CA, freedom from AF at two years was 85 and 72 percent, respectively [<a href="#rid12">12,13</a>]. (See  <a class="medical medical_review" href="/d/html/93920.html" rel="external">"Maintenance of sinus rhythm in atrial fibrillation: Catheter ablation versus antiarrhythmic drug therapy", section on 'Patients without prior antiarrhythmic drug treatment'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The 2019 CIRCA-DOSE study randomly assigned 346 patients with drug-refractory, paroxysmal AF to contact-force-guided RFA or two differing duration protocols for cryoballoon ablation [<a href="#rid1">1</a>] (see <a class="local">'Technical considerations'</a> above). All patients received an implantable loop recorder, and they also received noninvasive surveillance. Follow-up was for 12 months.</p><p></p><p class="bulletIndent1">The primary endpoint of one-year freedom from atrial tachyarrhythmia (symptomatic or asymptomatic) as detected by continuous rhythm monitoring was about 53 percent in the three groups. One-year freedom from symptomatic atrial tachyarrhythmia, defined by continuous monitoring, ranged between 73 and 79 percent (p = 0.87). AF burden was reduced by about 99 percent in the three groups (p = 0.36).</p><p></p><p class="headingAnchor" id="H2796629532"><span class="h2">Predictors of recurrence</span><span class="headingEndMark"> — </span>Recurrence is more likely in patients with underlying cardiovascular disease such as hypertension, complicated heart disease (including valvular heart disease), older age, persistent as opposed to paroxysmal AF, procedure performed at a low-volume center, untreated obstructive sleep apnea, obesity, increasing plasma B-type natriuretic peptide level, or left atrial (LA) dilation [<a href="#rid8">8,14-20</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>LA dilation </strong>– The success rate of CA is low in patients with long-standing persistent AF and severe LA dilation (&gt;5.5 cm).</p><p></p><p class="bulletIndent1">LA dilation should be assessed by volume determination rather than linear measurements if possible [<a href="#rid21">21</a>]. One study has shown that an LA volume ≥130 cc, assessed by computed tomography, predicts a recurrence rate of &gt;90 percent at one year [<a href="#rid22">22</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other LA remodeling parameters </strong>– Greater atrial wall thickness, lipid composition, and epicardial fat volume on cardiac computed tomography also predict AF recurrence in observational studies, but low measurement reproducibility may limit their clinical use [<a href="#rid23">23</a>]. Among 732 patients undergoing CA, 270 had AF recurrence after seven months. Patients with AF recurrence had higher LA wall thickness (anterior wall 1.9 versus 1.7 mm), epicardial adipose volume (145 versus 129 mm<sup>3</sup>) and lower LA wall attenuation reflective of higher lipid composition (-69.1 versus -67.5 Hounsfield Units).</p><p></p><p class="headingAnchor" id="H1142085929"><span class="h2">Comparison of radiofrequency and cryothermal ablation</span><span class="headingEndMark"> — </span>The commonly used approved energy sources for CA are RF and cryothermal ablation. The efficacy and safety associated with these two energy sources have been found to be similar in multiple studies [<a href="#rid1">1,24-29</a>].</p><p>The three major randomized trials comparing the two energy sources are as follows:</p><p class="bulletIndent1"><span class="glyph">●</span>In the FIRE AND ICE trial, 762 patients with symptomatic, drug-refractory, paroxysmal AF were randomly assigned to cryoballoon ablation or RFA [<a href="#rid30">30</a>]. The primary efficacy endpoint was the first documented clinical failure (eg, recurrence of AF, occurrence of atrial flutter or atrial tachycardia, use of antiarrhythmic drugs, or repeat ablation) following a 90-day blanking period after the index ablation. Arrhythmia surveillance was noninvasive.</p><p></p><p class="bulletIndent1">The mean duration of follow-up was 1.5 years. The primary efficacy endpoint was similar in both groups (34.6 versus 35.9 percent, respectively; hazard ratio 0.96, 95% CI 0.76-1.22).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In the FreezeAF trial, 315 patients with paroxysmal AF were randomly assigned to RFA or cryoballoon ablation [<a href="#rid25">25</a>]. The primary endpoint of freedom from atrial arrhythmia with absence of persistent complications was similar in the two groups at 12 months (70.7 versus 73.6 percent). Arrhythmia surveillance was noninvasive.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In the 2019 CIRCA-DOSE study, which is discussed above, the two energy sources led to similar efficacy outcomes. (See <a class="local">'How is recurrence defined and measured?'</a> above.)</p><p></p><p>Complications of cryoballoon ablation may differ somewhat from standard RFA. Pericardial effusions, tamponade, and atrioesophageal fistula have been reported less frequently in cryoballoon ablation. A recent international registry of AF-CA patients showed that atrial esophageal fistula was diagnosed in 0.038 percent with radiofrequency energy and 0.0015 percent with cryoballoon ablation [<a href="#rid31">31</a>]. Non-AF atrial tachyarrhythmias have also been less frequently reported in long-term follow-up of cryoballoon ablation. However, phrenic nerve paralysis has been reported in up to 6.3 percent of 1349 procedures, significantly higher than seen with standard RFA. Resolution occurs acutely in most patients and in &gt;90 percent within one year [<a href="#rid24">24</a>]. The use of larger balloons that prevent distal ablation and the assessment of diaphragmatic compound motor action potentials have lowered the rate of this complication. Recordings of diaphragmatic electromyograms during cryoballoon ablation for AF accurately predict phrenic nerve injury [<a href="#rid32">32</a>].</p><p class="headingAnchor" id="H1228813381"><span class="h2">Patients with persistent atrial fibrillation</span><span class="headingEndMark"> — </span>The majority of patients in the studies of CA presented above had paroxysmal AF. The efficacy of CA in patients with persistent AF is lower than in patients with paroxysmal AF [<a href="#rid33">33</a>]. Our threshold for recommending CA is higher for patients with persistent AF given the lower success rates. Also, we avoid the use of CA as first-line therapy in patients with persistent AF.</p><p>We believe CA is a reasonable choice for individuals with symptomatic persistent AF who either fail or cannot tolerate antiarrhythmic drug therapy or, in certain circumstances (ie, tachycardia-mediated cardiomyopathy), where there may be a benefit to maintaining sinus rhythm even in the absence of symptoms.</p><p>To improve outcomes, standard pulmonary vein isolation (PVI) with or without additional ablative lesions can be performed. The utility of these additional lesion sets has not been consistently demonstrated, and we therefore recommend standard PVI without the creation of additional lesions, including posterior wall isolation for the first ablation attempt in the majority of patients [<a href="#rid34">34</a>]. We consider additional lesions in patients with long-standing persistent AF or a markedly enlarged LA (see  <a class="medical medical_review" href="/d/html/1022.html" rel="external">"Atrial fibrillation: Overview and management of new-onset atrial fibrillation", section on 'Classification and terminology'</a>). In patients with persistent AF, one small randomized trial (VENUS) found that the addition of vein-of-Marshall ethanol (see  <a class="medical medical_review" href="/d/html/16402.html" rel="external">"Mechanisms of atrial fibrillation", section on 'Role of premature atrial complex and other arrhythmia triggers'</a>) infusion to catheter ablation, compared with catheter ablation alone, increased the likelihood of remaining free of AF at 6 and 12 months [<a href="#rid35">35</a>]. Further study of this procedure is needed.</p><p>A 2014 systematic review and meta-analysis identified 46 randomized trials and observational studies of 3819 patients who underwent CA for persistent AF [<a href="#rid36">36</a>]. Compared with medical therapy, CA reduced the risk of recurrent AF (odds ratio 0.32, 95% CI 0.20-0.53). Various ablation strategies were employed in the studies, and the most efficacious combined isolation of the PVs with limited linear ablation (eg, roof ablation, mitral isthmus ablation) within the LA. The success rate after two procedures was about 60 percent in all groups. (See <a class="local">'Comparison with antiarrhythmic therapy'</a> above.)</p><p>The STAR AF II trial was published subsequently to the meta-analysis [<a href="#rid2">2</a>]. In this trial, 589 patients with persistent AF were randomly assigned in a 1:4:4 ratio to ablation with PVI alone, PVI plus ablation of electrograms showing complex fractionated activity, or PVI plus additional linear ablation across the LA roof and mitral valve isthmus. There was no significant difference in the rates of the primary endpoint of freedom from any documented recurrence of AF lasting longer than 30 seconds after a single ablation procedure at 18 months (59 versus 49 versus 46 percent, respectively). Although serious adverse events appeared to be lower in the PVI-alone group, there were too few events for this endpoint to achieve statistical significance.</p><p class="headingAnchor" id="H1228813570"><span class="h2">Patients with concomitant atrial flutter</span><span class="headingEndMark"> — </span>Atrial fibrillation and flutter often coexist in part due to their common risk factors. In many atrial flutter patients, AF is thought to be the inciting arrhythmia, and as much as 55 percent of patients who undergo ablation for typical atrial flutter are also found to have AF on long-term follow-up [<a href="#rid37">37</a>]. Some studies have shown that PV triggers play an important role in the development of flutter [<a href="#rid38">38</a>].</p><p>While ablation of the tricuspid annulus-inferior vena cava (TA-IVC) isthmus is a highly successful treatment option for atrial flutter, the ablation approach to the patient with concomitant AF and atrial flutter requires a more extensive approach and has been evaluated:</p><p class="bulletIndent1"><span class="glyph">●</span>In a study of 108 patients with both AF and typical atrial flutter, patients were randomly assigned to either a dual-ablative procedure (PVI and TA-IVC isthmus ablation, 49 patients) or PVI alone (59 patients) [<a href="#rid39">39</a>]. After ablation, the following observations were made:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>During the first eight weeks post-procedure, none of the dual-procedure patients and 32 patients treated with PVI alone developed atrial flutter and required cardioversion and/or antiarrhythmic drugs.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>After eight weeks, all antiarrhythmic drugs were discontinued. Only three patients treated with PVI alone had further recurrences of atrial flutter, which was successfully treated with TA-IVC ablation. Seven of the dual-procedure patients and six of those treated with PVI alone developed recurrent AF. Of these 13 patients (12 percent of the total group), 10 underwent successful repeat PVI, and three remained in sinus rhythm on antiarrhythmic drugs.</p><p></p><p>These findings suggest that AF initiated by PV triggers may be the precursor rather than the consequence of atrial flutter. This conclusion is consistent with the observation that atrial flutter often starts after a transitional rhythm of variable duration, usually AF [<a href="#rid40">40,41</a>]. (See  <a class="medical medical_review" href="/d/html/1061.html" rel="external">"Electrocardiographic and electrophysiologic features of atrial flutter"</a>.)</p><p>Attempts to control all atrial arrhythmias in patients with atrial flutter by performing PVI alone or at the time of an atrial flutter ablation have been studied:</p><p class="bulletIndent1"><span class="glyph">●</span>In the Triple A trial, 60 patients with atrial flutter but no documented AF were randomized to receive antiarrhythmic drugs alone, ablation of the cavotricuspid isthmus (CTI), or PVI. The primary endpoint, defined as any recurrent atrial tachyarrhythmia, occurred in 82.4 percent of the drug-treated group, 60.9 percent in the CTI group, and 10 percent in the PVI group during a mean follow-up time of 1.42 years [<a href="#rid38">38</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In the PReVENT AF study [<a href="#rid42">42</a>], 50 patients with atrial flutter and no documented AF were randomized to CTI ablation alone or with concomitant PVI. More patients in the isthmus-ablation-only group experienced new-onset AF during follow-up (52 versus 12 percent), and the one-year burden also favored the combined ablation group compared with the isthmus-ablation-only group (8.3 versus 4 percent).</p><p></p><p>These findings suggest that PVI either alone or in conjunction with atrial flutter ablation may have a beneficial effect on long-term suppression of all atrial arrhythmias. However, we do not recommend performing this procedure in lieu of or at the time of TA-IVC ablation in patients whose only documented arrhythmia is atrial flutter given the potential risks associated with additional ablation. (See  <a class="medical medical_review" href="/d/html/1065.html" rel="external">"Atrial flutter: Maintenance of sinus rhythm"</a>.)</p><p class="headingAnchor" id="H34"><span class="h2">Patients with structural heart disease</span><span class="headingEndMark"> — </span>The presence of structural heart disease may influence both the safety and efficacy of ablation procedures.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Heart failure</strong> – CA appears to be safe and effective for the prevention of AF recurrence in patients with heart failure or impaired left ventricular function. The experience with ablation in this setting is discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/977.html" rel="external">"The management of atrial fibrillation in patients with heart failure", section on 'Rhythm control'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cardiac resynchronization therapy</strong> – CA as an alternative to cardiac resynchronization therapy with atrioventricular node ablation in patients with heart failure is discussed separately. (See  <a class="medical medical_review" href="/d/html/977.html" rel="external">"The management of atrial fibrillation in patients with heart failure", section on 'Preference for rhythm over rate control'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mitral valve prosthesis</strong> – A potential concern with CA in patients with a mitral valve prosthesis is injury to the valve. Furthermore, entrapment of the ablation catheter in a mechanical mitral valve, necessitating open-heart surgery, has been reported in patients undergoing left-sided ablation procedures. This issue was addressed in a report of 26 patients with mitral valve prostheses who were compared with a matched group of 52 patients without a mitral valve prosthesis [<a href="#rid43">43</a>]. The rate of maintenance of sinus rhythm was the same in the two groups, but the patients with a mitral valve prosthesis had longer fluoroscopy times with greater radiation exposure and a higher rate of post-ablation atrial tachycardia (23 versus 2 percent).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Rheumatic heart disease </strong>– The role of CA for chronic AF in patients with rheumatic heart disease (RHD)<strong> </strong>is not well defined. One study that compared 62 patients with AF, RHD, and mild mitral stenosis, and 124 matched patients without mitral stenosis, showed lower success rates (32 versus 57 percent) in those with RHD [<a href="#rid44">44</a>]. Another study performed electrophysiologic mapping in 17 patients with mitral stenosis who had chronic AF and were converted to sinus rhythm after balloon valvulotomy [<a href="#rid45">45</a>]. An organized atrial arrhythmia, which degenerated into AF, was induced in all patients; the focus was most often near the coronary sinus ostium. RFA was successful in 13 patients and, after a mean follow-up of 32 weeks, 10 were still in sinus rhythm.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cardiac surgery</strong> – Either the Maze procedure or off-pump CA using an epicardial approach should be considered in patients with AF and an indication for open-heart surgery. These approaches are not generally recommended for patients without an indication for cardiac surgery, except in special circumstances, because of the mortality and morbidity associated with surgery. (See  <a class="medical medical_review" href="/d/html/1046.html" rel="external">"Atrial fibrillation: Surgical ablation", section on 'Maze procedure'</a>.)</p><p></p><p class="headingAnchor" id="H1170207926"><span class="h2">Patients with hypertension</span><span class="headingEndMark"> — </span>Renal sympathetic nerve denervation has been proposed as an adjunctive treatment to CA in hypertensive AF patients. We do not feel the available evidence supports its use in this setting.</p><p>The rationale for the adding renal nerve denervation to CA is that hypertension is a major risk factor for the development of AF and that many hypertensive AF patients have increased sympathetic tone. Renal nerve denervation has been evaluated as a treatment for hypertension, but its efficacy has not yet been established. (See  <a class="medical medical_review" href="/d/html/3819.html" rel="external">"Treatment of resistant hypertension"</a>.)</p><p>The issue of whether renal nerve denervation, when added to CA, can further lower the rate of AF recurrence was evaluated in the ERADICATE-AF trial [<a href="#rid46">46</a>]. In this study, 302 hypertensive (paroxysmal) AF patients were randomly assigned to CA or CA plus renal nerve denervation. The primary endpoint of freedom from AF, atrial flutter, or tachycardia at 12 months occurred in 56.5 and 72.1 percent of the two groups, respectively (hazard ratio 0.57, 95% CI 0.38-0.85). There was no significant difference in the rate of procedural complications between the two groups. Although the use of renal denervation as adjunctive therapy to CA improved the primary outcome, the lack of a sham-control group, that is CA plus sham renal denervation, is a major limitation of this study.</p><p class="headingAnchor" id="H39"><span class="h1">COMPLICATIONS</span><span class="headingEndMark"> — </span>The types and rates of complications that occur in patients undergoing CA vary from series to series  (<a class="graphic graphic_table graphicRef127127" href="/d/graphic/127127.html" rel="external">table 1</a> and <a class="graphic graphic_table graphicRef127125" href="/d/graphic/127125.html" rel="external">table 2</a>). The overall rate of major complications is about 4 percent, with vascular access complications being the most frequent [<a href="#rid47">47</a>]. There may be an increased rate of adverse effects with more extensive circumferential ablation [<a href="#rid48">48-52</a>]. A meta-analysis of 89 studies including 15,701 patients showed an overall and severe procedure-related complication rate of 4.5 and 2.4 percent, respectively [<a href="#rid53">53</a>]. (See  <a class="medical medical_review" href="/d/html/95704.html" rel="external">"Catheter ablation for the treatment of atrial fibrillation: Technical considerations for non-electrophysiologists", section on 'Ablation techniques and targets'</a>.)</p><p>There are conflicting reports as to whether the complication rate has fallen with time:</p><p class="bulletIndent1"><span class="glyph">●</span>An analysis of 93,801 CA procedures performed in community hospitals in the United States between 2000 and 2010 did not identify a trend toward lower mortality [<a href="#rid54">54</a>]. The majority (81 percent) of procedures were performed in low-volume hospitals by low-volume operators. The overall frequency of complications was 6.29 percent, and there was a small but nonsignificant rise with time.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a meta-analysis of 192 published studies, including 83,236 patients, there was a significant decrease in the acute complication rate from 2007 to 2012 compared with 2000 to 2006 (2.6 versus 4 percent; p = 0.003) [<a href="#rid55">55</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>An analysis of 15,701 patients from 89 studies showed that reported complication rates were lower in studies from 2013 to 2017 compared with 2018 to 2022 (5.3 versus 3.8 percent) [<a href="#rid53">53</a>].</p><p></p><p>In these studies, cardiac complications accounted for at least 50 percent of all complications. Most [<a href="#rid54">54,56</a>], but not all [<a href="#rid57">57</a>], studies have suggested that advanced age and female sex are risk factors for complications. In addition, annual operator (&lt;25 procedures) and hospital volume (&lt;50 procedures) have been associated with adverse outcomes [<a href="#rid54">54</a>].</p><p>Complications reported in series of patients undergoing CA to prevent recurrent AF will be reviewed here. Other complications that might occur with any electrophysiology study, such as radiation exposure and valve, vascular, or myocardial injury, are discussed separately. (See  <a class="medical medical_review" href="/d/html/1007.html" rel="external">"Overview of catheter ablation of cardiac arrhythmias", section on 'Complications'</a>.)</p><p class="headingAnchor" id="H40"><span class="h2">Mortality</span><span class="headingEndMark"> — </span>Early case series found a death rate of about 1 to 1.5 in every 1000 patients [<a href="#rid58">58,59</a>]. More recent studies suggest a mortality closer to 5 per 1000.</p><p>A recent meta-analysis of studies performed between 2013 and 2022 showed a mortality of around 0.06 percent. Leading causes of death include cardiac tamponade and stroke. Other causes included pneumonia, pulmonary vein (PV) perforation, and sepsis [<a href="#rid58">58</a>].</p><p class="headingAnchor" id="H2944026021"><span class="h2">Pericarditis</span><span class="headingEndMark"> — </span>Pericarditis may occur as an early response to myocardial and/or pericardial injury caused by the ablation procedure. In a series of 1540 patients who underwent catheter ablation for AF, acute pericarditis was diagnosed in 57 patients (3.7 percent) [<a href="#rid60">60</a>]. The median symptom onset was one day after the procedure, and mean duration of treatment (with nonsteroidal antiinflammatory drugs with or without <a class="drug drug_general" data-topicid="9293" href="/d/drug information/9293.html" rel="external">colchicine</a>) was seven days. Cardiac tamponade was identified in only four patients (7 percent of patients with pericarditis). Radiofrequency ablation (rather than cryoablation) and younger age were independent risk factors for acute pericarditis postablation.</p><p>A delayed onset post-cardiac injury syndrome has also been reported following ablation procedures. (See  <a class="medical medical_review" href="/d/html/4915.html" rel="external">"Post-cardiac injury syndromes"</a>.)</p><p class="headingAnchor" id="H41"><span class="h2">Cardiac tamponade</span><span class="headingEndMark"> — </span>Cardiac tamponade resulting from perforation is the most frequent serious complication of CA for AF, occurring in slightly more than 1 percent of procedures using radiofrequency (RF) [<a href="#rid56">56,58,61</a>], and it is the leading cause of death [<a href="#rid58">58</a>]. Tamponade results from either catheter perforation of an atrial or ventricular free wall, especially with overheating during energy delivery, or less frequently with transseptal puncture. Some cases of tamponade may be caused by pericarditis; this may explain some cases with delayed onset. In one study of delayed tamponade, the median duration was 10 days, with a range of several hours up to 30 days [<a href="#rid58">58</a>]. Pericardial effusion associated with PV isolation (PVI) was significantly less common in patients who underwent cryoballoon ablation (0.8 versus 2.1 percent) in one meta-analysis [<a href="#rid29">29</a>], but a second meta-analysis showed no difference [<a href="#rid62">62</a>]. The treatment of tamponade caused by CA is similar to that in other settings. (See  <a class="medical medical_review" href="/d/html/143123.html" rel="external">"Pericardial effusion: Approach to management", section on 'Indications for pericardial fluid removal'</a>.)</p><p class="headingAnchor" id="H85423607"><span class="h2">Catheter entrapment</span><span class="headingEndMark"> — </span>Entrapment of the circular mapping (LASSO) catheter in the mitral valve apparatus is a rare complication that can require cardiac surgery to resolve. The estimated incidence of this complication ranges between 0.01 and 0.9 percent, and specific sites of transeptal puncture or catheter manipulation may predispose to this adverse event [<a href="#rid63">63-65</a>].</p><p class="headingAnchor" id="H42"><span class="h2">Pulmonary vein stenosis</span><span class="headingEndMark"> — </span>PV stenosis is a potential complication of ablation near or within the PVs. The lesion is characterized by fibrosis and scarring of the PV; specific pathologic changes include intimal thickening, thrombus formation, endocardial contraction, and proliferation of elastic laminae [<a href="#rid66">66</a>]. The diagnosis may be delayed or missed entirely, as symptomatic patients may come to attention months after their initial ablation. In one series, symptoms developed 4 ± 3 months after the most recent ablation, and the average delay between the onset of symptoms and diagnosis was 4.4 ± 5.4 months. Symptoms of PV stenosis include dyspnea with exertion (or less often at rest), cough, chest pain, hemoptysis, and recurrent lung infections [<a href="#rid67">67,68</a>]. The mean onset of symptoms is two to five months after the procedure [<a href="#rid67">67-69</a>]. The intensity of symptoms may be directly related to the degree of obstruction and inversely related to the duration of time to develop the stenosis [<a href="#rid70">70</a>]. Incorrect diagnoses including pneumonia, bronchitis, or suspected malignancy are often considered and result in unnecessary testing, treatment, and delayed intervention. Delays in diagnosis and treatment may allow for progression of stenosis and irreversible intraparenchymal lung damage.</p><p>The reported rate of PV stenosis depends not only on the factors described above, but also on the definition of stenosis severity and the intensity of screening. Early reports cited rates as high as 38 percent, but more studies cite rates for severe stenosis as low as 1 to 3 percent [<a href="#rid56">56,63,68,71</a>]. A minority of diagnosed patients appear to develop symptoms [<a href="#rid72">72,73</a>]. The incidence of severe PV stenosis is between 0.32 and 3.4 percent, but the risk may be lower with cryoballoon compared with radiofrequency energy [<a href="#rid74">74</a>]. The rate of PV stenosis requiring intervention may be as low as 0.1 to 0.3 percent [<a href="#rid61">61</a>].</p><p>Diagnostic evaluation for PV stenosis should be performed in patients who develop respiratory symptoms after RF ablation (RFA). The joint Heart Rhythm Society/European Heart Rhythm Association/European Cardiac Arrhythmia Society expert consensus statement of catheter and surgical ablation of AF suggests computed tomography or magnetic resonance imaging (MRI) as the preferred tests in suspected cases [<a href="#rid70">70</a>]. A ventilation/perfusion lung scan can also be used to diagnose PV stenosis.</p><p>Stent placement is a more effective therapy for PV stenosis compared with balloon angioplasty [<a href="#rid74">74</a>]. It is associated with a significant and almost immediate improvement in symptoms and pulmonary blood flow [<a href="#rid67">67-69</a>]. In series of patients who underwent balloon angioplasty with or without stenting, in-segment or in-stent stenosis requiring repeat intervention developed in approximately 50 percent of patients [<a href="#rid68">68,69</a>]. The roles of either elective stenting or surgery are not well defined [<a href="#rid70">70</a>]. However, the incidence of PV stenosis has significantly decreased due to improvement in ablative techniques, especially with moving the ablation lesions toward the atrial side of the PV-atrial junction.</p><p class="headingAnchor" id="H46"><span class="h2">Periprocedural embolic events</span><span class="headingEndMark"> — </span>Patients undergoing CA to prevent recurrent AF are at risk for embolic events before, during, and after the procedure. The incidence of clinical stroke or transient ischemic attack is between 0 and 2 percent [<a href="#rid9">9</a>]. The role of anticoagulant therapy in this setting is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/94502.html" rel="external">"Catheter ablation to prevent recurrent atrial fibrillation: Anticoagulation"</a>.)</p><p class="headingAnchor" id="H709039557"><span class="h2">MRI-detected brain lesions and cognitive impairment</span><span class="headingEndMark"> — </span>Stroke and transient ischemic attack are not the only neurologic sequelae of CA. Multiple MRI studies performed within 24 hours after RFA have demonstrated new cerebral lesions in 7 to 44 percent of asymptomatic patients [<a href="#rid75">75-77</a>]. However, in a study of 60 AF patients at relatively low risk for stroke who underwent CA, only one patient developed new asymptomatic lesions on MRI soon after the procedure [<a href="#rid78">78</a>]. These lesions were presumed secondary to microemboli [<a href="#rid79">79</a>].</p><p>Studies of the impact of these lesions on neurocognitive function have come to differing conclusions as to the significance of these lesions, as illustrated by the following studies:</p><p class="bulletIndent1"><span class="glyph">●</span>The prevalence of cognitive impairment after RFA was evaluated in a study of 150 patients: 60 undergoing ablation for paroxysmal AF, 30 for persistent AF, 30 for supraventricular tachycardia, and 30 matched AF patients awaiting RFA (the control group) [<a href="#rid80">80</a>]. All RFA patients received periprocedural <a class="drug drug_general" data-topicid="9407" href="/d/drug information/9407.html" rel="external">enoxaparin</a>, and most patients with AF had a CHADS<sub>2</sub> score of 0 or 1  (<a class="graphic graphic_table graphicRef61615" href="/d/graphic/61615.html" rel="external">table 3</a>). All patients underwent eight neuropsychological tests at baseline and at 2 and 90 days after RFA. The prevalence of neurocognitive dysfunction at day 90 was 13, 20, 3, and 0 percent, respectively.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a study of 37 patients with paroxysmal AF who underwent 41 ablation procedures, MRI performed within 48 hours showed new brain lesions in 41 percent of patients and 44 percent of procedures [<a href="#rid77">77</a>]. Follow-up MRI at six months found glial scar in about 12 percent of those with lesions. However, there was no decline of neurocognitive function on testing.</p><p></p><p class="headingAnchor" id="H16900209"><span class="h2">Vascular complications</span><span class="headingEndMark"> — </span>Vascular complications are among the most common adverse events related to AF ablation, likely due to the number and size of intravascular sheaths and the need for anticoagulation both during and immediately following the procedure. These complications include hematoma at the sites of catheter insertion, pseudoaneurysm, arteriovenous fistula, or retroperitoneal bleeding. Pseudoaneurysm and arteriovenous fistulae rates of 0.53 and 0.43 percent, respectively, have been reported [<a href="#rid61">61,63</a>]. This risk can be significantly reduced by the use of vascular ultrasound, which was demonstrated, in one study of 689 patients, to reduce the risk of vascular access complications from 5.3 to 1.1 percent [<a href="#rid81">81</a>]. Conservative management alone is usually sufficient for large hematomas and retroperitoneal bleeding, though anticoagulation may need to be held, and transfusion may be necessary in those patients where the risks of such interventions are warranted. Echo-guided manual compression and percutaneous intervention are usually effective treatments of femoral pseudoaneurysms or arteriovenous fistula, but direct surgical intervention is sometimes required [<a href="#rid82">82</a>].</p><p class="headingAnchor" id="H1061746086"><span class="h2">Atrial esophageal fistula</span><span class="headingEndMark"> — </span>This is a potentially life-threatening medical emergency for which the exact mechanism is unknown. The overall incidence is 0.3 to 0.54 percent, and mortality is between 50 and 83 percent [<a href="#rid83">83</a>]. A more recent international registry of patients with AF-CA showed that atrial esophageal fistula was diagnosed in 0.038 percent who had ablation with radiofrequency energy and 0.0015 percent who had cryoballoon ablation [<a href="#rid31">31</a>]. Early recognition can be missed due to the low awareness of this rare complication. It is important for patients to be educated as to warning signs and to contact their AF ablation center should any suggestive symptoms develop. Clinical manifestations usually present one to four weeks post-ablation (range of 2 to 60 days), and the most common symptoms are fever, chest pain, and recurrent neurologic events from septic emboli. Chest computed tomography is the preferred diagnostic modality. Endoscopy with air insufflation should not be performed.</p><p class="headingAnchor" id="H1228811936"><span class="h2">Arrhythmic complications</span><span class="headingEndMark"> — </span>New reentrant circuits created by the ablation lesions can lead to atypical left atrial (LA) flutter. These circuits tend to develop around regions of LA scar and often involve the perimitral region. Due to anatomic variability and technical challenges, successful ablation is more difficult than that for typical right atrial flutter involving the isthmus of the inferior vena cava and tricuspid annulus. A significant percentage of LA flutter following PVI may also involve the musculature of the coronary sinus or the roof of the left atrium [<a href="#rid84">84</a>]. (See  <a class="medical medical_review" href="/d/html/1061.html" rel="external">"Electrocardiographic and electrophysiologic features of atrial flutter"</a>.)</p><p>Typical atrial flutter may also occur after LA ablation due to alterations in activation patterns of the LA and may have an unusual electrocardiographic morphology.</p><p>LA flutter appears to be more common following circumferential (as opposed to segmental) PVI [<a href="#rid51">51,84-87</a>]. In a randomized comparison of circumferential and segmental PVI, LA flutter developed in 9 of the 50 patients undergoing circumferential PVI, and in 1 of the 50 patients in the segmental PVI group [<a href="#rid51">51</a>].</p><p>In addition, many of the recurrent LA arrhythmias following segmental PVI are focal atrial tachycardias, as opposed to macroreentrant flutter circuits, and are often successfully treated with repeat isolation of the PVs.</p><p class="headingAnchor" id="H571858431"><span class="h2">Other</span><span class="headingEndMark"> — </span>Other complications with their respective incidences are summarized:</p><p class="bulletIndent1"><span class="glyph">●</span>Phrenic nerve injury (&lt;1 percent) [<a href="#rid61">61,63</a>] in patients receiving RFA (and up to 6.3 percent in those receiving cryoablation). (See <a class="local">'Comparison of radiofrequency and cryothermal ablation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Periesophageal vagal injury (gastric hypomotility) [<a href="#rid50">50,88</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Acute coronary artery occlusion/injury (&lt;1 percent) [<a href="#rid70">70,89</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Iatrogenic atrial septal defect after cryoballoon ablation without clinical consequence (20 percent) [<a href="#rid90">90</a>].</p><p></p><p class="headingAnchor" id="H700377964"><span class="h1">PREVENTION OF RECURRENCE</span><span class="headingEndMark"> — </span>The following therapies have been evaluated for their ability to prevent late recurrent AF; only treatment of obstructive sleep apnea (OSA) seems to be beneficial:</p><p class="bulletIndent1"><strong>Glucocorticoid therapy</strong> – We do not believe there is sufficient evidence to recommend the use of prophylactic glucocorticoid therapy.</p><p></p><p class="bulletIndent1">Two observations raise the possibility that corticosteroid therapy might be useful for the prevention of early recurrence. Firstly, inflammation is associated with the development of AF, and systemic and local inflammatory responses may result from radiofrequency ablation (RFA) [<a href="#rid91">91</a>] (see  <a class="medical medical_review" href="/d/html/1004.html" rel="external">"Epidemiology, risk factors, and prevention of atrial fibrillation", section on 'Inflammation and infection'</a>). Secondly, glucocorticoid prophylaxis reduces the risk of the development of perioperative AF in patients undergoing coronary artery bypass graft surgery. (See  <a class="medical medical_review" href="/d/html/1011.html" rel="external">"Atrial fibrillation and flutter after cardiac surgery", section on 'Ineffective or possibly effective therapies'</a>.)</p><p></p><p class="bulletIndent1">The possible benefit from prophylactic glucocorticoid therapy was evaluated in a study of 125 patients with paroxysmal AF who were randomly assigned to either three days of glucocorticoid therapy or placebo starting immediately after the procedure [<a href="#rid92">92</a>]. The rate of AF recurrence (primary endpoint) was significantly lower in the glucocorticoid group at one month (27 versus 49 percent), with most of the benefit occurring during the first three days (7 versus 31 percent).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment of OSA</strong> – OSA is a predictor of recurrent AF after RFA. Patients with OSA who undergo CA should be encouraged to be evaluated for treatment with continuous positive airway pressure [<a href="#rid93">93,94</a>]. (See  <a class="medical medical_review" href="/d/html/7706.html" rel="external">"Clinical presentation and diagnosis of obstructive sleep apnea in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9293" href="/d/drug information/9293.html" rel="external">Colchicine</a> – Colchicine, another drug with antiinflammatory properties, has been shown to decrease the risk of postoperative AF after cardiac surgery, particularly in patients with post-pericardiotomy syndrome. However, pending additional studies showing benefit, we do not use prophylactic colchicine. (See  <a class="medical medical_review" href="/d/html/4915.html" rel="external">"Post-cardiac injury syndromes", section on 'Prevention'</a>.)</p><p></p><p class="bulletIndent1">The potential ability of <a class="drug drug_general" data-topicid="9293" href="/d/drug information/9293.html" rel="external">colchicine</a> to reduce the incidence of early recurrent AF after pulmonary vein isolation was evaluated in a study of 206 individuals with paroxysmal AF who were randomly assigned to colchicine 0.5 mg twice daily or placebo beginning on the day of CA and continuing for three months [<a href="#rid95">95</a>]. After follow-up of about 15 months, there was a lower recurrence rate of AF in patients taking colchicine (31.1 versus 49.5 percent; odds ratio [OR] 0.46, 95% CI 0.26-0.81).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Angiotensin inhibition</strong> – The data are mixed as to whether angiotensin converting enzyme inhibitors/angiotensin II receptor blockers reduce AF after CA procedures. This issue is discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/935.html" rel="external">"ACE inhibitors, angiotensin receptor blockers, and atrial fibrillation", section on 'Catheter ablation of atrial fibrillation'</a>.)</p><p></p><p class="bulletIndent1"><strong>Periprocedural weight reduction </strong>– Some studies suggest that periprocedural weight reduction may be a helpful adjunct to CA.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Pre-procedure weight reduction</strong> – In a retrospective study of 600 patients, weight reduction before CA was associated with reduced AF occurrence [<a href="#rid96">96</a>]. Freedom from AF was observed in 420 patients (70 percent) at 15 months. Percent weight loss during the year before CA independently predicted freedom from AF through the next 15 months (OR 1.17, 95% CI 1.11-1.23).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Post-procedure weight reduction </strong>– The SORT-AF Study compared one-year AF burden in patients with obesity participating in a weight loss program versus usual care after CA [<a href="#rid97">97</a>]. The intervention group had a small reduction in weight loss (5 versus 1 kg in controls). AF burden (measured with implantable loop recorder) after ablation did not differ between the two groups (OR 1.14, 95% CI 0.37-3.6). However, a reduction in body mass index was associated with a decrease in AF recurrence in persistent compared with paroxysmal AF patients.</p><p></p><p class="headingAnchor" id="H1228811624"><span class="h1">FOLLOW-UP</span><span class="headingEndMark"> — </span>Surveillance for recurrence of atrial arrhythmias is important in patients who have undergone CA. We agree with the joint Heart Rhythm Society/European Heart Rhythm Association/European Cardiac Arrhythmia Society expert consensus statement of catheter and surgical ablation of AF [<a href="#rid70">70</a>], which recommends the following:</p><p class="bulletIndent1"><span class="glyph">●</span>First visit with electrophysiologist at a minimum of three months, and then every six months for at least two years.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Electrocardiograms (ECGs) at all visits; symptomatic (eg, palpitations) patients should be evaluated with some form of event monitoring.</p><p></p><p>The optimal method for screening for episodes of AF after ablation is not known. In the above studies, late recurrent AF was detected by patient symptoms, serial ECGs, 24- to 48-hour Holter monitoring, and implantable cardiac monitor [<a href="#rid10">10,14,98,99</a>]. Rhythm transmitters were also used in the first few months [<a href="#rid99">99</a>]. With the exceptions of implantable cardiac monitor, preexisting dual-chamber pacemaker, or implantable cardioverter-defibrillator with AF detection capabilities, these methods may underestimate the incidence of recurrence due to sampling error [<a href="#rid100">100</a>]. In addition, as has been well demonstrated, patients with AF have a high rate of asymptomatic episodes. (See  <a class="medical medical_review" href="/d/html/956.html" rel="external">"Paroxysmal atrial fibrillation", section on 'Natural history'</a> and <a class="local">'Efficacy'</a> above.)</p><p class="headingAnchor" id="H1228812906"><span class="h1">MANAGEMENT OF RECURRENCE</span><span class="headingEndMark"> — </span>Some patients with symptomatic AF after CA are candidates for a repeat procedure. The decision to do so is usually based on a patient's assessment of the potential benefit and risks. Other patients may choose a trial of antiarrhythmic drug therapy to reduce symptoms.</p><p>The most common reason for recurrence of paroxysmal AF is reconnection of previously ablated electrically active tissue. Based upon the recurrence rates of AF after ablation, many patients are candidates for repeat ablation. We tell our patients that the success rate is in the range of 50 to 85 percent for a single procedure based primarily on AF type and anatomy, and that about 20 percent of patients have at least a second procedure. Success rates after a second procedure can be as high as 90 percent. Some experts and patients have agreed to repeat the procedure a third time. Patients with a history of persistent AF have a lower success rate and are less often felt to be good candidates for repeat procedures.</p><p>The issue of whether patients with AF recurrence should undergo a repeat procedure or be placed on antiarrhythmic drug therapy was addressed in a study that randomly assigned 154 patients with symptomatic, paroxysmal AF recurrence to either repeat ablation or antiarrhythmic drugs [<a href="#rid101">101</a>]. During three-year follow-up, fewer patients in the repeat ablation group demonstrated AF progression, defined as an increase in AF burden &gt;30 percent relative to baseline based on insertable cardiac monitor (also sometimes referred to as implantable cardiac monitor or implantable loop recorder) data or development of persistent AF (25 versus 79 percent; p&lt;0.01). Despite limitations of this study, it supports our approach of offering a second ablation procedure to most patients.</p><p class="headingAnchor" id="H1246384129"><span class="h1">CONTRAINDICATIONS</span><span class="headingEndMark"> — </span>While there are few absolute contraindications, the risks and benefits of AF ablation should be carefully considered in each patient.</p><p>Contraindications to AF ablation include preexisting left atrial or left atrial appendage thrombus, inability to safely administer anticoagulation during or after the procedure, inability to tolerate sedation, patients with atrial septal defect closure devices in whom transseptal access cannot be performed, and those with interruption of the inferior vena cava. While not contraindicated, ablations performed on those with very long-standing persistent AF (ie, &gt;2 years), severe mitral stenosis or regurgitation, or large left atria are expected to have lower success rates. (See <a class="local">'Predictors of recurrence'</a> above.)</p><p class="headingAnchor" id="H3673814392"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/112091.html" rel="external">"Society guideline links: Atrial fibrillation"</a> and  <a class="medical medical_society_guidelines" href="/d/html/112260.html" rel="external">"Society guideline links: Arrhythmias in adults"</a>.)</p><p class="headingAnchor" id="H57"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, “The Basics” and “Beyond the Basics.” The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on “patient info” and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/d/html/3431.html" rel="external">"Patient education: Atrial fibrillation (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H58"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Role of catheter ablation (CA) </strong>– CA for atrial fibrillation (AF) leads to symptom improvement in many patients. However, it has not convincingly been shown to decrease the risks of embolization (eg, stroke) or death. (See <a class="local">'Efficacy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy </strong>– Current techniques for CA should lead to one-year freedom from symptomatic AF while off antiarrhythmic drug therapy in about 75 to 90 percent of patients with drug-resistant paroxysmal AF and no significant structural heart disease. (See <a class="local">'Efficacy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Complications </strong>– Important complications of CA include pericarditis, cardiac tamponade, stroke, vascular trauma, and phrenic nerve palsy, and, rarely, death  (<a class="graphic graphic_table graphicRef127125" href="/d/graphic/127125.html" rel="external">table 2</a>). Specific signs and symptoms can help identify complications  (<a class="graphic graphic_table graphicRef127127" href="/d/graphic/127127.html" rel="external">table 1</a>) . (See <a class="local">'Complications'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Recurrence </strong>– For patients who have recurrent AF after a first ablation, there are two reasonable management strategies: a clinical trial of an antiarrhythmic agent or proceeding directly to a second ablation. Patients may have a preference for one or the other. (See <a class="local">'Management of recurrence'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Andrade JG, Champagne J, Dubuc M, et al. Cryoballoon or Radiofrequency Ablation for Atrial Fibrillation Assessed by Continuous Monitoring: A Randomized Clinical Trial. Circulation 2019; 140:1779.</a></li><li><a class="nounderline abstract_t">Verma A, Jiang CY, Betts TR, et al. Approaches to catheter ablation for persistent atrial fibrillation. N Engl J Med 2015; 372:1812.</a></li><li><a class="nounderline abstract_t">Arbelo E, Brugada J, Hindricks G, et al. The atrial fibrillation ablation pilot study: a European Survey on Methodology and results of catheter ablation for atrial fibrillation conducted by the European Heart Rhythm Association. Eur Heart J 2014; 35:1466.</a></li><li><a class="nounderline abstract_t">Cheng EP, Liu CF, Yeo I, et al. Risk of Mortality Following Catheter Ablation of Atrial Fibrillation. J Am Coll Cardiol 2019; 74:2254.</a></li><li><a class="nounderline abstract_t">Ouyang F, Antz M, Ernst S, et al. Recovered pulmonary vein conduction as a dominant factor for recurrent atrial tachyarrhythmias after complete circular isolation of the pulmonary veins: lessons from double Lasso technique. Circulation 2005; 111:127.</a></li><li><a class="nounderline abstract_t">Oral H, Knight BP, Ozaydin M, et al. Clinical significance of early recurrences of atrial fibrillation after pulmonary vein isolation. J Am Coll Cardiol 2002; 40:100.</a></li><li><a class="nounderline abstract_t">Mugnai G, de Asmundis C, Hünük B, et al. Second-generation cryoballoon ablation for paroxysmal atrial fibrillation: Predictive role of atrial arrhythmias occurring in the blanking period on the incidence of late recurrences. Heart Rhythm 2016; 13:845.</a></li><li><a class="nounderline abstract_t">Lubitz SA, Fischer A, Fuster V. Catheter ablation for atrial fibrillation. BMJ 2008; 336:819.</a></li><li><a class="nounderline abstract_t">Calkins H, Hindricks G, Cappato R, et al. 2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation. Heart Rhythm 2017; 14:e275.</a></li><li><a class="nounderline abstract_t">Verma A, Champagne J, Sapp J, et al. Discerning the incidence of symptomatic and asymptomatic episodes of atrial fibrillation before and after catheter ablation (DISCERN AF): a prospective, multicenter study. JAMA Intern Med 2013; 173:149.</a></li><li><a class="nounderline abstract_t">Ngo L, Lee XW, Elwashahy M, et al. Freedom from atrial arrhythmia and other clinical outcomes at 5 years and beyond after catheter ablation of atrial fibrillation: a systematic review and meta-analysis. Eur Heart J Qual Care Clin Outcomes 2023; 9:447.</a></li><li><a class="nounderline abstract_t">Cosedis Nielsen J, Johannessen A, Raatikainen P, et al. Radiofrequency ablation as initial therapy in paroxysmal atrial fibrillation. N Engl J Med 2012; 367:1587.</a></li><li><a class="nounderline abstract_t">Morillo CA, Verma A, Connolly SJ, et al. Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of paroxysmal atrial fibrillation (RAAFT-2): a randomized trial. JAMA 2014; 311:692.</a></li><li><a class="nounderline abstract_t">Pappone C, Oreto G, Rosanio S, et al. Atrial electroanatomic remodeling after circumferential radiofrequency pulmonary vein ablation: efficacy of an anatomic approach in a large cohort of patients with atrial fibrillation. Circulation 2001; 104:2539.</a></li><li><a class="nounderline abstract_t">Marine JE. Catheter ablation therapy for supraventricular arrhythmias. JAMA 2007; 298:2768.</a></li><li><a class="nounderline abstract_t">Berruezo A, Tamborero D, Mont L, et al. Pre-procedural predictors of atrial fibrillation recurrence after circumferential pulmonary vein ablation. Eur Heart J 2007; 28:836.</a></li><li><a class="nounderline abstract_t">Miyazaki S, Kuwahara T, Kobori A, et al. Catheter ablation of atrial fibrillation in patients with valvular heart disease: long-term follow-up results. J Cardiovasc Electrophysiol 2010; 21:1193.</a></li><li><a class="nounderline abstract_t">Balk EM, Garlitski AC, Alsheikh-Ali AA, et al. Predictors of atrial fibrillation recurrence after radiofrequency catheter ablation: a systematic review. J Cardiovasc Electrophysiol 2010; 21:1208.</a></li><li><a class="nounderline abstract_t">Hussein AA, Saliba WI, Martin DO, et al. Plasma B-type natriuretic peptide levels and recurrent arrhythmia after successful ablation of lone atrial fibrillation. Circulation 2011; 123:2077.</a></li><li><a class="nounderline abstract_t">Gami AS, Pressman G, Caples SM, et al. Association of atrial fibrillation and obstructive sleep apnea. Circulation 2004; 110:364.</a></li><li><a class="nounderline abstract_t">Lang RM, Bierig M, Devereux RB, et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 2005; 18:1440.</a></li><li><a class="nounderline abstract_t">Parikh SS, Jons C, McNitt S, et al. Predictive capability of left atrial size measured by CT, TEE, and TTE for recurrence of atrial fibrillation following radiofrequency catheter ablation. Pacing Clin Electrophysiol 2010; 33:532.</a></li><li><a class="nounderline abstract_t">Beyer C, Tokarska L, Stühlinger M, et al. Structural Cardiac Remodeling in Atrial Fibrillation. JACC Cardiovasc Imaging 2021; 14:2199.</a></li><li><a class="nounderline abstract_t">Andrade JG, Khairy P, Guerra PG, et al. Efficacy and safety of cryoballoon ablation for atrial fibrillation: a systematic review of published studies. Heart Rhythm 2011; 8:1444.</a></li><li><a class="nounderline abstract_t">Luik A, Radzewitz A, Kieser M, et al. Cryoballoon versus open irrigated radiofrequency ablation in patients with paroxysmal atrial fibrillation: The prospective, randomized, controlled, noninferiority FreezeAF Study. Circulation 2015; 132:1311.</a></li><li><a class="nounderline abstract_t">Schmidt M, Dorwarth U, Andresen D, et al. Cryoballoon versus RF ablation in paroxysmal atrial fibrillation: results from the German Ablation Registry. J Cardiovasc Electrophysiol 2014; 25:1.</a></li><li><a class="nounderline abstract_t">Linhart M, Bellmann B, Mittmann-Braun E, et al. Comparison of cryoballoon and radiofrequency ablation of pulmonary veins in 40 patients with paroxysmal atrial fibrillation: a case-control study. J Cardiovasc Electrophysiol 2009; 20:1343.</a></li><li><a class="nounderline abstract_t">Kojodjojo P, O'Neill MD, Lim PB, et al. Pulmonary venous isolation by antral ablation with a large cryoballoon for treatment of paroxysmal and persistent atrial fibrillation: medium-term outcomes and non-randomised comparison with pulmonary venous isolation by radiofrequency ablation. Heart 2010; 96:1379.</a></li><li><a class="nounderline abstract_t">Cardoso R, Mendirichaga R, Fernandes G, et al. Cryoballoon versus Radiofrequency Catheter Ablation in Atrial Fibrillation: A Meta-Analysis. J Cardiovasc Electrophysiol 2016; 27:1151.</a></li><li><a class="nounderline abstract_t">Kuck KH, Brugada J, Fürnkranz A, et al. Cryoballoon or Radiofrequency Ablation for Paroxysmal Atrial Fibrillation. N Engl J Med 2016; 374:2235.</a></li><li><a class="nounderline abstract_t">Tilz RR, Schmidt V, Pürerfellner H, et al. A worldwide survey on incidence, management, and prognosis of oesophageal fistula formation following atrial fibrillation catheter ablation: the POTTER-AF study. Eur Heart J 2023; 44:2458.</a></li><li><a class="nounderline abstract_t">Lakhani M, Saiful F, Parikh V, et al. Recordings of diaphragmatic electromyograms during cryoballoon ablation for atrial fibrillation accurately predict phrenic nerve injury. Heart Rhythm 2014; 11:369.</a></li><li><a class="nounderline abstract_t">Brooks AG, Stiles MK, Laborderie J, et al. Outcomes of long-standing persistent atrial fibrillation ablation: a systematic review. Heart Rhythm 2010; 7:835.</a></li><li><a class="nounderline abstract_t">Kistler PM, Chieng D, Sugumar H, et al. Effect of Catheter Ablation Using Pulmonary Vein Isolation With vs Without Posterior Left Atrial Wall Isolation on Atrial Arrhythmia Recurrence in Patients With Persistent Atrial Fibrillation: The CAPLA Randomized Clinical Trial. JAMA 2023; 329:127.</a></li><li><a class="nounderline abstract_t">Valderrábano M, Peterson LE, Swarup V, et al. Effect of Catheter Ablation With Vein of Marshall Ethanol Infusion vs Catheter Ablation Alone on Persistent Atrial Fibrillation: The VENUS Randomized Clinical Trial. JAMA 2020; 324:1620.</a></li><li><a class="nounderline abstract_t">Wynn GJ, Das M, Bonnett LJ, et al. Efficacy of catheter ablation for persistent atrial fibrillation: a systematic review and meta-analysis of evidence from randomized and nonrandomized controlled trials. Circ Arrhythm Electrophysiol 2014; 7:841.</a></li><li><a class="nounderline abstract_t">Mittal S, Pokushalov E, Romanov A, et al. Long-term ECG monitoring using an implantable loop recorder for the detection of atrial fibrillation after cavotricuspid isthmus ablation in patients with atrial flutter. Heart Rhythm 2013; 10:1598.</a></li><li><a class="nounderline abstract_t">Schneider R, Lauschke J, Tischer T, et al. Pulmonary vein triggers play an important role in the initiation of atrial flutter: Initial results from the prospective randomized Atrial Fibrillation Ablation in Atrial Flutter (Triple A) trial. Heart Rhythm 2015; 12:865.</a></li><li><a class="nounderline abstract_t">Wazni O, Marrouche NF, Martin DO, et al. Randomized study comparing combined pulmonary vein-left atrial junction disconnection and cavotricuspid isthmus ablation versus pulmonary vein-left atrial junction disconnection alone in patients presenting with typical atrial flutter and atrial fibrillation. Circulation 2003; 108:2479.</a></li><li><a class="nounderline abstract_t">Waldo AL, Cooper TB. Spontaneous onset of type I atrial flutter in patients. J Am Coll Cardiol 1996; 28:707.</a></li><li><a class="nounderline abstract_t">Waldo AL. Mechanisms of atrial flutter and atrial fibrillation: distinct entities or two sides of a coin? Cardiovasc Res 2002; 54:217.</a></li><li><a class="nounderline abstract_t">Steinberg JS, Romanov A, Musat D, et al. Prophylactic pulmonary vein isolation during isthmus ablation for atrial flutter: the PReVENT AF Study I. Heart Rhythm 2014; 11:1567.</a></li><li><a class="nounderline abstract_t">Lang CC, Santinelli V, Augello G, et al. Transcatheter radiofrequency ablation of atrial fibrillation in patients with mitral valve prostheses and enlarged atria: safety, feasibility, and efficacy. J Am Coll Cardiol 2005; 45:868.</a></li><li><a class="nounderline abstract_t">Chen J, Wang H, Zhao L. Long-term outcomes of radiofrequency catheter ablation for atrial fibrillation in rheumatic heart disease patients with mild mitral stenosis. J Interv Card Electrophysiol 2019; 56:313.</a></li><li><a class="nounderline abstract_t">Nair M, Shah P, Batra R, et al. Chronic atrial fibrillation in patients with rheumatic heart disease: mapping and radiofrequency ablation of flutter circuits seen at initiation after cardioversion. Circulation 2001; 104:802.</a></li><li><a class="nounderline abstract_t">Steinberg JS, Shabanov V, Ponomarev D, et al. Effect of Renal Denervation and Catheter Ablation vs Catheter Ablation Alone on Atrial Fibrillation Recurrence Among Patients With Paroxysmal Atrial Fibrillation and Hypertension: The ERADICATE-AF Randomized Clinical Trial. JAMA 2020; 323:248.</a></li><li><a class="nounderline abstract_t">Bertaglia E, Stabile G, Pappone A, et al. Updated national multicenter registry on procedural safety of catheter ablation for atrial fibrillation. J Cardiovasc Electrophysiol 2013; 24:1069.</a></li><li><a class="nounderline abstract_t">Pappone C, Oral H, Santinelli V, et al. Atrio-esophageal fistula as a complication of percutaneous transcatheter ablation of atrial fibrillation. Circulation 2004; 109:2724.</a></li><li><a class="nounderline abstract_t">Scanavacca MI, D'ávila A, Parga J, Sosa E. Left atrial-esophageal fistula following radiofrequency catheter ablation of atrial fibrillation. J Cardiovasc Electrophysiol 2004; 15:960.</a></li><li><a class="nounderline abstract_t">Shah D, Dumonceau JM, Burri H, et al. Acute pyloric spasm and gastric hypomotility: an extracardiac adverse effect of percutaneous radiofrequency ablation for atrial fibrillation. J Am Coll Cardiol 2005; 46:327.</a></li><li><a class="nounderline abstract_t">Karch MR, Zrenner B, Deisenhofer I, et al. Freedom from atrial tachyarrhythmias after catheter ablation of atrial fibrillation: a randomized comparison between 2 current ablation strategies. Circulation 2005; 111:2875.</a></li><li><a class="nounderline abstract_t">Oral H, Scharf C, Chugh A, et al. Catheter ablation for paroxysmal atrial fibrillation: segmental pulmonary vein ostial ablation versus left atrial ablation. Circulation 2003; 108:2355.</a></li><li><a class="nounderline abstract_t">Benali K, Khairy P, Hammache N, et al. Procedure-Related Complications of Catheter Ablation for Atrial Fibrillation. J Am Coll Cardiol 2023; 81:2089.</a></li><li><a class="nounderline abstract_t">Deshmukh A, Patel NJ, Pant S, et al. In-hospital complications associated with catheter ablation of atrial fibrillation in the United States between 2000 and 2010: analysis of 93 801 procedures. Circulation 2013; 128:2104.</a></li><li><a class="nounderline abstract_t">Gupta A, Perera T, Ganesan A, et al. Complications of catheter ablation of atrial fibrillation: a systematic review. Circ Arrhythm Electrophysiol 2013; 6:1082.</a></li><li><a class="nounderline abstract_t">Spragg DD, Dalal D, Cheema A, et al. Complications of catheter ablation for atrial fibrillation: incidence and predictors. J Cardiovasc Electrophysiol 2008; 19:627.</a></li><li><a class="nounderline abstract_t">Zado E, Callans DJ, Riley M, et al. Long-term clinical efficacy and risk of catheter ablation for atrial fibrillation in the elderly. J Cardiovasc Electrophysiol 2008; 19:621.</a></li><li><a class="nounderline abstract_t">Cappato R, Calkins H, Chen SA, et al. Prevalence and causes of fatal outcome in catheter ablation of atrial fibrillation. J Am Coll Cardiol 2009; 53:1798.</a></li><li><a class="nounderline abstract_t">Cappato R, Calkins H, Chen SA, et al. Updated worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation. Circ Arrhythm Electrophysiol 2010; 3:32.</a></li><li><a class="nounderline abstract_t">Yadav R, Satti DI, Malwankar J, et al. Pericarditis After Catheter Ablation for Atrial Fibrillation: Predictors and Outcomes. JACC Clin Electrophysiol 2023.</a></li><li><a class="nounderline abstract_t">Maan A, Shaikh AY, Mansour M, et al. Complications from catheter ablation of atrial fibrillation: a systematic review. Crit Pathw Cardiol 2011; 10:76.</a></li><li><a class="nounderline abstract_t">Kim JA, Chelu MG. Comparison of cryoballoon and radiofrequency ablation for persistent atrial fibrillation: a systematic review and meta-analysis. J Interv Card Electrophysiol 2023; 66:585.</a></li><li><a class="nounderline abstract_t">Cappato R, Calkins H, Chen SA, et al. Worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation. Circulation 2005; 111:1100.</a></li><li><a class="nounderline abstract_t">Zeljko HM, Mont L, Sitges M, et al. Entrapment of the circular mapping catheter in the mitral valve in two patients undergoing atrial fibrillation ablation. Europace 2011; 13:132.</a></li><li><a class="nounderline abstract_t">Kesek M, Englund A, Jensen SM, Jensen-Urstad M. Entrapment of circular mapping catheter in the mitral valve. Heart Rhythm 2007; 4:17.</a></li><li><a class="nounderline abstract_t">Taylor GW, Kay GN, Zheng X, et al. Pathological effects of extensive radiofrequency energy applications in the pulmonary veins in dogs. Circulation 2000; 101:1736.</a></li><li><a class="nounderline abstract_t">Saad EB, Marrouche NF, Saad CP, et al. Pulmonary vein stenosis after catheter ablation of atrial fibrillation: emergence of a new clinical syndrome. Ann Intern Med 2003; 138:634.</a></li><li><a class="nounderline abstract_t">Packer DL, Keelan P, Munger TM, et al. Clinical presentation, investigation, and management of pulmonary vein stenosis complicating ablation for atrial fibrillation. Circulation 2005; 111:546.</a></li><li><a class="nounderline abstract_t">Qureshi AM, Prieto LR, Latson LA, et al. Transcatheter angioplasty for acquired pulmonary vein stenosis after radiofrequency ablation. Circulation 2003; 108:1336.</a></li><li><a class="nounderline abstract_t">European Heart Rhythm Association (EHRA), European Cardiac Arrhythmia Scoiety (ECAS), American College of Cardiology (ACC), et al. HRS/EHRA/ECAS expert Consensus Statement on catheter and surgical ablation of atrial fibrillation: recommendations for personnel, policy, procedures and follow-up. A report of the Heart Rhythm Society (HRS) Task Force on catheter and surgical ablation of atrial fibrillation. Heart Rhythm 2007; 4:816.</a></li><li><a class="nounderline abstract_t">Saad EB, Rossillo A, Saad CP, et al. Pulmonary vein stenosis after radiofrequency ablation of atrial fibrillation: functional characterization, evolution, and influence of the ablation strategy. Circulation 2003; 108:3102.</a></li><li><a class="nounderline abstract_t">Arentz T, Weber R, Jander N, et al. Pulmonary haemodynamics at rest and during exercise in patients with significant pulmonary vein stenosis after radiofrequency catheter ablation for drug resistant atrial fibrillation. Eur Heart J 2005; 26:1410.</a></li><li><a class="nounderline abstract_t">Di Biase L, Fahmy TS, Wazni OM, et al. Pulmonary vein total occlusion following catheter ablation for atrial fibrillation: clinical implications after long-term follow-up. J Am Coll Cardiol 2006; 48:2493.</a></li><li><a class="nounderline abstract_t">Fender EA, Widmer RJ, Hodge DO, et al. Severe Pulmonary Vein Stenosis Resulting From Ablation for Atrial Fibrillation: Presentation, Management, and Clinical Outcomes. Circulation 2016; 134:1812.</a></li><li><a class="nounderline abstract_t">Gaita F, Caponi D, Pianelli M, et al. Radiofrequency catheter ablation of atrial fibrillation: a cause of silent thromboembolism? Magnetic resonance imaging assessment of cerebral thromboembolism in patients undergoing ablation of atrial fibrillation. Circulation 2010; 122:1667.</a></li><li><a class="nounderline abstract_t">Schrickel JW, Lickfett L, Lewalter T, et al. Incidence and predictors of silent cerebral embolism during pulmonary vein catheter ablation for atrial fibrillation. Europace 2010; 12:52.</a></li><li><a class="nounderline abstract_t">Herm J, Fiebach JB, Koch L, et al. Neuropsychological effects of MRI-detected brain lesions after left atrial catheter ablation for atrial fibrillation: long-term results of the MACPAF study. Circ Arrhythm Electrophysiol 2013; 6:843.</a></li><li><a class="nounderline abstract_t">Verma A, Debruyne P, Nardi S, et al. Evaluation and reduction of asymptomatic cerebral embolism in ablation of atrial fibrillation, but high prevalence of chronic silent infarction: results of the evaluation of reduction of asymptomatic cerebral embolism trial. Circ Arrhythm Electrophysiol 2013; 6:835.</a></li><li><a class="nounderline abstract_t">Haines DE. ERACEing the risk of cerebral embolism from atrial fibrillation ablation. Circ Arrhythm Electrophysiol 2013; 6:827.</a></li><li><a class="nounderline abstract_t">Medi C, Evered L, Silbert B, et al. Subtle post-procedural cognitive dysfunction after atrial fibrillation ablation. J Am Coll Cardiol 2013; 62:531.</a></li><li><a class="nounderline abstract_t">Sharma PS, Padala SK, Gunda S, et al. Vascular complications during catheter ablation of cardiac arrhythmias: A comparison between vascular ultrasound guided access and conventional vascular access. J Cardiovasc Electrophysiol 2016; 27:1160.</a></li><li><a class="nounderline abstract_t">Waigand J, Uhlich F, Gross CM, et al. Percutaneous treatment of pseudoaneurysms and arteriovenous fistulas after invasive vascular procedures. Catheter Cardiovasc Interv 1999; 47:157.</a></li><li><a class="nounderline abstract_t">Calkins H, Hindricks G, Cappato R, et al. 2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation: Executive summary. J Arrhythm 2017; 33:369.</a></li><li><a class="nounderline abstract_t">Chugh A, Oral H, Good E, et al. Catheter ablation of atypical atrial flutter and atrial tachycardia within the coronary sinus after left atrial ablation for atrial fibrillation. J Am Coll Cardiol 2005; 46:83.</a></li><li><a class="nounderline abstract_t">Kanagaratnam L, Tomassoni G, Schweikert R, et al. Empirical pulmonary vein isolation in patients with chronic atrial fibrillation using a three-dimensional nonfluoroscopic mapping system: long-term follow-up. Pacing Clin Electrophysiol 2001; 24:1774.</a></li><li><a class="nounderline abstract_t">Cummings JE, Schweikert R, Saliba W, et al. Left atrial flutter following pulmonary vein antrum isolation with radiofrequency energy: linear lesions or repeat isolation. J Cardiovasc Electrophysiol 2005; 16:293.</a></li><li><a class="nounderline abstract_t">Gerstenfeld EP, Callans DJ, Dixit S, et al. Mechanisms of organized left atrial tachycardias occurring after pulmonary vein isolation. Circulation 2004; 110:1351.</a></li><li><a class="nounderline abstract_t">Dumonceau JM, Giostra E, Bech C, et al. Acute delayed gastric emptying after ablation of atrial fibrillation: treatment with botulinum toxin injection. Endoscopy 2006; 38:543.</a></li><li><a class="nounderline abstract_t">Roberts-Thomson KC, Steven D, Seiler J, et al. Coronary artery injury due to catheter ablation in adults: presentations and outcomes. Circulation 2009; 120:1465.</a></li><li><a class="nounderline abstract_t">Sieira J, Chierchia GB, Di Giovanni G, et al. One year incidence of iatrogenic atrial septal defect after cryoballoon ablation for atrial fibrillation. J Cardiovasc Electrophysiol 2014; 25:11.</a></li><li><a class="nounderline abstract_t">Koyama T, Sekiguchi Y, Tada H, et al. Comparison of characteristics and significance of immediate versus early versus no recurrence of atrial fibrillation after catheter ablation. Am J Cardiol 2009; 103:1249.</a></li><li><a class="nounderline abstract_t">Koyama T, Tada H, Sekiguchi Y, et al. Prevention of atrial fibrillation recurrence with corticosteroids after radiofrequency catheter ablation: a randomized controlled trial. J Am Coll Cardiol 2010; 56:1463.</a></li><li><a class="nounderline abstract_t">Fein AS, Shvilkin A, Shah D, et al. Treatment of obstructive sleep apnea reduces the risk of atrial fibrillation recurrence after catheter ablation. J Am Coll Cardiol 2013; 62:300.</a></li><li><a class="nounderline abstract_t">Naruse Y, Tada H, Satoh M, et al. Concomitant obstructive sleep apnea increases the recurrence of atrial fibrillation following radiofrequency catheter ablation of atrial fibrillation: clinical impact of continuous positive airway pressure therapy. Heart Rhythm 2013; 10:331.</a></li><li><a class="nounderline abstract_t">Deftereos S, Giannopoulos G, Efremidis M, et al. Colchicine for prevention of atrial fibrillation recurrence after pulmonary vein isolation: mid-term efficacy and effect on quality of life. Heart Rhythm 2014; 11:620.</a></li><li><a class="nounderline abstract_t">Peigh G, Wasserlauf J, Vogel K, et al. Impact of pre-ablation weight loss on the success of catheter ablation for atrial fibrillation. J Cardiovasc Electrophysiol 2021; 32:2097.</a></li><li><a class="nounderline abstract_t">Gessler N, Willems S, Steven D, et al. Supervised Obesity Reduction Trial for AF ablation patients: results from the SORT-AF trial. Europace 2021; 23:1548.</a></li><li><a class="nounderline abstract_t">Pappone C, Rosanio S, Augello G, et al. Mortality, morbidity, and quality of life after circumferential pulmonary vein ablation for atrial fibrillation: outcomes from a controlled nonrandomized long-term study. J Am Coll Cardiol 2003; 42:185.</a></li><li><a class="nounderline abstract_t">Verma A, Wazni OM, Marrouche NF, et al. Pre-existent left atrial scarring in patients undergoing pulmonary vein antrum isolation: an independent predictor of procedural failure. J Am Coll Cardiol 2005; 45:285.</a></li><li><a class="nounderline abstract_t">Senatore G, Stabile G, Bertaglia E, et al. Role of transtelephonic electrocardiographic monitoring in detecting short-term arrhythmia recurrences after radiofrequency ablation in patients with atrial fibrillation. J Am Coll Cardiol 2005; 45:873.</a></li><li><a class="nounderline abstract_t">Pokushalov E, Romanov A, De Melis M, et al. Progression of atrial fibrillation after a failed initial ablation procedure in patients with paroxysmal atrial fibrillation: a randomized comparison of drug therapy versus reablation. Circ Arrhythm Electrophysiol 2013; 6:754.</a></li></ol></div><div id="topicVersionRevision">Topic 949 Version 70.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31630538" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Cryoballoon or Radiofrequency Ablation for Atrial Fibrillation Assessed by Continuous Monitoring: A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25946280" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Approaches to catheter ablation for persistent atrial fibrillation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24487524" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : The atrial fibrillation ablation pilot study: a European Survey on Methodology and results of catheter ablation for atrial fibrillation conducted by the European Heart Rhythm Association.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31672181" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Risk of Mortality Following Catheter Ablation of Atrial Fibrillation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15623542" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Recovered pulmonary vein conduction as a dominant factor for recurrent atrial tachyarrhythmias after complete circular isolation of the pulmonary veins: lessons from double Lasso technique.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12103262" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Clinical significance of early recurrences of atrial fibrillation after pulmonary vein isolation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26724490" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Second-generation cryoballoon ablation for paroxysmal atrial fibrillation: Predictive role of atrial arrhythmias occurring in the blanking period on the incidence of late recurrences.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18403546" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Catheter ablation for atrial fibrillation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28506916" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : 2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23266597" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Discerning the incidence of symptomatic and asymptomatic episodes of atrial fibrillation before and after catheter ablation (DISCERN AF): a prospective, multicenter study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37336617" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Freedom from atrial arrhythmia and other clinical outcomes at 5 years and beyond after catheter ablation of atrial fibrillation: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23094720" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Radiofrequency ablation as initial therapy in paroxysmal atrial fibrillation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24549549" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of paroxysmal atrial fibrillation (RAAFT-2): a randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11714647" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Atrial electroanatomic remodeling after circumferential radiofrequency pulmonary vein ablation: efficacy of an anatomic approach in a large cohort of patients with atrial fibrillation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18165670" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Catheter ablation therapy for supraventricular arrhythmias.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17395676" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Pre-procedural predictors of atrial fibrillation recurrence after circumferential pulmonary vein ablation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20550616" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Catheter ablation of atrial fibrillation in patients with valvular heart disease: long-term follow-up results.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20487117" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Predictors of atrial fibrillation recurrence after radiofrequency catheter ablation: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21536999" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Plasma B-type natriuretic peptide levels and recurrent arrhythmia after successful ablation of lone atrial fibrillation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15249509" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Association of atrial fibrillation and obstructive sleep apnea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16376782" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20132503" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Predictive capability of left atrial size measured by CT, TEE, and TTE for recurrence of atrial fibrillation following radiofrequency catheter ablation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34147453" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Structural Cardiac Remodeling in Atrial Fibrillation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21457789" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Efficacy and safety of cryoballoon ablation for atrial fibrillation: a systematic review of published studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26283655" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Cryoballoon versus open irrigated radiofrequency ablation in patients with paroxysmal atrial fibrillation: The prospective, randomized, controlled, noninferiority FreezeAF Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24134539" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Cryoballoon versus RF ablation in paroxysmal atrial fibrillation: results from the German Ablation Registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19656254" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Comparison of cryoballoon and radiofrequency ablation of pulmonary veins in 40 patients with paroxysmal atrial fibrillation: a case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20801856" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Pulmonary venous isolation by antral ablation with a large cryoballoon for treatment of paroxysmal and persistent atrial fibrillation: medium-term outcomes and non-randomised comparison with pulmonary venous isolation by radiofrequency ablation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27422848" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Cryoballoon versus Radiofrequency Catheter Ablation in Atrial Fibrillation: A Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27042964" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Cryoballoon or Radiofrequency Ablation for Paroxysmal Atrial Fibrillation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37062040" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : A worldwide survey on incidence, management, and prognosis of oesophageal fistula formation following atrial fibrillation catheter ablation: the POTTER-AF study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24252287" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Recordings of diaphragmatic electromyograms during cryoballoon ablation for atrial fibrillation accurately predict phrenic nerve injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20206320" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Outcomes of long-standing persistent atrial fibrillation ablation: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36625809" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Effect of Catheter Ablation Using Pulmonary Vein Isolation With vs Without Posterior Left Atrial Wall Isolation on Atrial Arrhythmia Recurrence in Patients With Persistent Atrial Fibrillation: The CAPLA Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33107945" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Effect of Catheter Ablation With Vein of Marshall Ethanol Infusion vs Catheter Ablation Alone on Persistent Atrial Fibrillation: The VENUS Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25132078" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Efficacy of catheter ablation for persistent atrial fibrillation: a systematic review and meta-analysis of evidence from randomized and nonrandomized controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23911429" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Long-term ECG monitoring using an implantable loop recorder for the detection of atrial fibrillation after cavotricuspid isthmus ablation in patients with atrial flutter.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25638698" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Pulmonary vein triggers play an important role in the initiation of atrial flutter: Initial results from the prospective randomized Atrial Fibrillation Ablation in Atrial Flutter (Triple A) trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14610012" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Randomized study comparing combined pulmonary vein-left atrial junction disconnection and cavotricuspid isthmus ablation versus pulmonary vein-left atrial junction disconnection alone in patients presenting with typical atrial flutter and atrial fibrillation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8772760" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Spontaneous onset of type I atrial flutter in patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12062328" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Mechanisms of atrial flutter and atrial fibrillation: distinct entities or two sides of a coin?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24832767" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Prophylactic pulmonary vein isolation during isthmus ablation for atrial flutter: the PReVENT AF Study I.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15766822" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Transcatheter radiofrequency ablation of atrial fibrillation in patients with mitral valve prostheses and enlarged atria: safety, feasibility, and efficacy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31055689" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Long-term outcomes of radiofrequency catheter ablation for atrial fibrillation in rheumatic heart disease patients with mild mitral stenosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11502706" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Chronic atrial fibrillation in patients with rheumatic heart disease: mapping and radiofrequency ablation of flutter circuits seen at initiation after cardioversion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31961420" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Effect of Renal Denervation and Catheter Ablation vs Catheter Ablation Alone on Atrial Fibrillation Recurrence Among Patients With Paroxysmal Atrial Fibrillation and Hypertension: The ERADICATE-AF Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23799876" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Updated national multicenter registry on procedural safety of catheter ablation for atrial fibrillation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15159294" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Atrio-esophageal fistula as a complication of percutaneous transcatheter ablation of atrial fibrillation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15333097" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Left atrial-esophageal fistula following radiofrequency catheter ablation of atrial fibrillation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16022963" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Acute pyloric spasm and gastric hypomotility: an extracardiac adverse effect of percutaneous radiofrequency ablation for atrial fibrillation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15927974" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Freedom from atrial tachyarrhythmias after catheter ablation of atrial fibrillation: a randomized comparison between 2 current ablation strategies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14557355" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Catheter ablation for paroxysmal atrial fibrillation: segmental pulmonary vein ostial ablation versus left atrial ablation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37225362" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Procedure-Related Complications of Catheter Ablation for Atrial Fibrillation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24061087" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : In-hospital complications associated with catheter ablation of atrial fibrillation in the United States between 2000 and 2010: analysis of 93 801 procedures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24243785" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Complications of catheter ablation of atrial fibrillation: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18462327" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Complications of catheter ablation for atrial fibrillation: incidence and predictors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18462325" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Long-term clinical efficacy and risk of catheter ablation for atrial fibrillation in the elderly.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19422987" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Prevalence and causes of fatal outcome in catheter ablation of atrial fibrillation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19995881" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Updated worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/38032577" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Pericarditis After Catheter Ablation for Atrial Fibrillation: Predictors and Outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21988947" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Complications from catheter ablation of atrial fibrillation: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36089635" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Comparison of cryoballoon and radiofrequency ablation for persistent atrial fibrillation: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15723973" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21149514" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Entrapment of the circular mapping catheter in the mitral valve in two patients undergoing atrial fibrillation ablation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17198983" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Entrapment of circular mapping catheter in the mitral valve.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10758058" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Pathological effects of extensive radiofrequency energy applications in the pulmonary veins in dogs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12693885" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Pulmonary vein stenosis after catheter ablation of atrial fibrillation: emergence of a new clinical syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15699274" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Clinical presentation, investigation, and management of pulmonary vein stenosis complicating ablation for atrial fibrillation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12952852" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Transcatheter angioplasty for acquired pulmonary vein stenosis after radiofrequency ablation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17556213" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : HRS/EHRA/ECAS expert Consensus Statement on catheter and surgical ablation of atrial fibrillation: recommendations for personnel, policy, procedures and follow-up. A report of the Heart Rhythm Society (HRS) Task Force on catheter and surgical ablation of atrial fibrillation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14623799" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Pulmonary vein stenosis after radiofrequency ablation of atrial fibrillation: functional characterization, evolution, and influence of the ablation strategy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15855192" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Pulmonary haemodynamics at rest and during exercise in patients with significant pulmonary vein stenosis after radiofrequency catheter ablation for drug resistant atrial fibrillation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17174188" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Pulmonary vein total occlusion following catheter ablation for atrial fibrillation: clinical implications after long-term follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27793993" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Severe Pulmonary Vein Stenosis Resulting From Ablation for Atrial Fibrillation: Presentation, Management, and Clinical Outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20937975" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Radiofrequency catheter ablation of atrial fibrillation: a cause of silent thromboembolism? Magnetic resonance imaging assessment of cerebral thromboembolism in patients undergoing ablation of atrial fibrillation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19933517" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Incidence and predictors of silent cerebral embolism during pulmonary vein catheter ablation for atrial fibrillation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23989301" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Neuropsychological effects of MRI-detected brain lesions after left atrial catheter ablation for atrial fibrillation: long-term results of the MACPAF study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23983245" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Evaluation and reduction of asymptomatic cerebral embolism in ablation of atrial fibrillation, but high prevalence of chronic silent infarction: results of the evaluation of reduction of asymptomatic cerebral embolism trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24129202" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : ERACEing the risk of cerebral embolism from atrial fibrillation ablation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23684686" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Subtle post-procedural cognitive dysfunction after atrial fibrillation ablation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27433795" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Vascular complications during catheter ablation of cardiac arrhythmias: A comparison between vascular ultrasound guided access and conventional vascular access.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10376495" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Percutaneous treatment of pseudoaneurysms and arteriovenous fistulas after invasive vascular procedures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29021841" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : 2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation: Executive summary.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15992640" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Catheter ablation of atypical atrial flutter and atrial tachycardia within the coronary sinus after left atrial ablation for atrial fibrillation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11817811" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Empirical pulmonary vein isolation in patients with chronic atrial fibrillation using a three-dimensional nonfluoroscopic mapping system: long-term follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15817089" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Left atrial flutter following pulmonary vein antrum isolation with radiofrequency energy: linear lesions or repeat isolation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15353501" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Mechanisms of organized left atrial tachycardias occurring after pulmonary vein isolation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16767599" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Acute delayed gastric emptying after ablation of atrial fibrillation: treatment with botulinum toxin injection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19786630" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Coronary artery injury due to catheter ablation in adults: presentations and outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24118262" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : One year incidence of iatrogenic atrial septal defect after cryoballoon ablation for atrial fibrillation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19406267" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Comparison of characteristics and significance of immediate versus early versus no recurrence of atrial fibrillation after catheter ablation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20951321" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Prevention of atrial fibrillation recurrence with corticosteroids after radiofrequency catheter ablation: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23623910" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Treatment of obstructive sleep apnea reduces the risk of atrial fibrillation recurrence after catheter ablation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23178687" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Concomitant obstructive sleep apnea increases the recurrence of atrial fibrillation following radiofrequency catheter ablation of atrial fibrillation: clinical impact of continuous positive airway pressure therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24508207" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Colchicine for prevention of atrial fibrillation recurrence after pulmonary vein isolation: mid-term efficacy and effect on quality of life.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34191371" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Impact of pre-ablation weight loss on the success of catheter ablation for atrial fibrillation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33895833" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Supervised Obesity Reduction Trial for AF ablation patients: results from the SORT-AF trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12875749" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Mortality, morbidity, and quality of life after circumferential pulmonary vein ablation for atrial fibrillation: outcomes from a controlled nonrandomized long-term study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15653029" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Pre-existent left atrial scarring in patients undergoing pulmonary vein antrum isolation: an independent predictor of procedural failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15766823" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Role of transtelephonic electrocardiographic monitoring in detecting short-term arrhythmia recurrences after radiofrequency ablation in patients with atrial fibrillation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23748210" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Progression of atrial fibrillation after a failed initial ablation procedure in patients with paroxysmal atrial fibrillation: a randomized comparison of drug therapy versus reablation.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
